Tendencia del PSA en pacientes con carcinoma de próstata metastásico manejados con orquiectomía vs. bloqueo hormonal con análogos de la hormona liberadora de gonadotrofinas

Translated title of the contribution: PSA trends in patients with metastatic prostate cancer managed by orquiectomyvs hormone block by gonadotropin releasing hormone analogues

Nicolás Fernández, Nicolas Villareal, Rodolfo Varela

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Current standard treatment for metastatic prostate carcinoma is hormone therapy.The two most commonly used treatments are orchiectomy and gonadotropin releasing hormone (GnRH) analogues, both being equivalent. There is no data regarding the PSA trends in our population. This is the first study that analyzes these issues, and will serve for future studies. Methods: A retrospective cohort study was performed on patients with metastatic prostate cancer (CaPM) who underwent orchiectomy or started treatment with GnRH analogues and were followed over time in order to evaluate the trends of PSA and other associated variables such as, patient age, initial PSA, Gleason score. and TNM. Results: A total of 124 patients were included in the study and divided into two groups; the Orchiectomy (OQ) and the GnRH analogues (BA) group. Monthly PSA records were analyzed and there were no differences in PSA levels over time in these two groups. Progression occurred earlier in the OQ group at 27 months vs 32 months in the BA group. Conclusions: Both treatments are equivalent. Progression occurred earlier in the OQ group. Further studies are needed to measure the specific impact of administrative and insurance issues in the treatment of these patients.

Translated title of the contributionPSA trends in patients with metastatic prostate cancer managed by orquiectomyvs hormone block by gonadotropin releasing hormone analogues
Original languageSpanish
Pages (from-to)183-187
Number of pages5
JournalUrologia Colombiana
Volume23
Issue number3
DOIs
StatePublished - 1 Dec 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'PSA trends in patients with metastatic prostate cancer managed by orquiectomyvs hormone block by gonadotropin releasing hormone analogues'. Together they form a unique fingerprint.

Cite this